相似文献
1
Severe acute respiratory syndrome (SARS) coronavirus: application of monoclonal antibodies and development of an effective vaccine.
Rev Med Virol. 2006 Mar-Apr;16(2):117-31. doi: 10.1002/rmv.492.
2
Human monoclonal antibodies to the S glycoprotein and related proteins as potential therapeutics for SARS.
Curr Opin Mol Ther. 2005 Apr;7(2):151-6.
3
Induction of specific immune responses by severe acute respiratory syndrome coronavirus spike DNA vaccine with or without interleukin-2 immunization using different vaccination routes in mice.
Clin Vaccine Immunol. 2007 Jul;14(7):894-901. doi: 10.1128/CVI.00019-07. Epub 2007 May 9.
4
The possible of immunotherapy for COVID-19: A systematic review.
Int Immunopharmacol. 2020 Jun;83:106455. doi: 10.1016/j.intimp.2020.106455. Epub 2020 Apr 2.
5
Epitope mapping and biological function analysis of antibodies produced by immunization of mice with an inactivated Chinese isolate of severe acute respiratory syndrome-associated coronavirus (SARS-CoV).
Virology. 2005 Mar 30;334(1):134-43. doi: 10.1016/j.virol.2005.01.035.
6
Severe acute respiratory syndrome vaccine efficacy in ferrets: whole killed virus and adenovirus-vectored vaccines.
J Gen Virol. 2008 Sep;89(Pt 9):2136-2146. doi: 10.1099/vir.0.2008/001891-0.
7
Monoclonal antibodies for the S2 subunit of spike of SARS-CoV-1 cross-react with the newly-emerged SARS-CoV-2.
Euro Surveill. 2020 Jul;25(28). doi: 10.2807/1560-7917.ES.2020.25.28.2000291.
8
Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine.
Antivir Ther. 2007;12(7):1107-13.
9
Neutralizing antibody against severe acute respiratory syndrome (SARS)-coronavirus spike is highly effective for the protection of mice in the murine SARS model.
Microbiol Immunol. 2009 Feb;53(2):75-82. doi: 10.1111/j.1348-0421.2008.00097.x.
10
Fully human monoclonal antibody directed to proteolytic cleavage site in severe acute respiratory syndrome (SARS) coronavirus S protein neutralizes the virus in a rhesus macaque SARS model.
J Infect Dis. 2011 Jun 1;203(11):1574-81. doi: 10.1093/infdis/jir084.
引用本文的文献
1
Application of Traditional Vaccine Development Strategies to SARS-CoV-2.
mSystems. 2023 Apr 27;8(2):e0092722. doi: 10.1128/msystems.00927-22. Epub 2023 Mar 2.
2
Application of Traditional Vaccine Development Strategies to SARS-CoV-2.
ArXiv. 2023 Jan 23:arXiv:2208.08907v2.
3
Emergence, evolution, and vaccine production approaches of SARS-CoV-2 virus: Benefits of getting vaccinated and common questions.
Saudi J Biol Sci. 2022 Apr;29(4):1981-1997. doi: 10.1016/j.sjbs.2021.12.020. Epub 2021 Dec 13.
4
COVID-19: Coronavirus Vaccine Development Updates.
Front Immunol. 2020 Dec 23;11:602256. doi: 10.3389/fimmu.2020.602256. eCollection 2020.
5
An overview of viruses discovered over the last decades and drug development for the current pandemic.
Eur J Pharmacol. 2021 Jan 5;890:173746. doi: 10.1016/j.ejphar.2020.173746. Epub 2020 Nov 19.
6
Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past.
Front Immunol. 2020 Aug 7;11:1949. doi: 10.3389/fimmu.2020.01949. eCollection 2020.
7
Coronaviruses: An Updated Overview of Their Replication and Pathogenesis.
Methods Mol Biol. 2020;2203:1-29. doi: 10.1007/978-1-0716-0900-2_1.
8
SARS-CoV-2 S1 is superior to the RBD as a COVID-19 subunit vaccine antigen.
J Med Virol. 2021 Feb;93(2):892-898. doi: 10.1002/jmv.26320. Epub 2020 Oct 5.
9
The Hemagglutinin Stem-Binding Monoclonal Antibody VIS410 Controls Influenza Virus-Induced Acute Respiratory Distress Syndrome.
Antimicrob Agents Chemother. 2016 Mar 25;60(4):2118-31. doi: 10.1128/AAC.02457-15. Print 2016 Apr.
10
Substitution at aspartic acid 1128 in the SARS coronavirus spike glycoprotein mediates escape from a S2 domain-targeting neutralizing monoclonal antibody.
PLoS One. 2014 Jul 14;9(7):e102415. doi: 10.1371/journal.pone.0102415. eCollection 2014.
本文引用的文献
1
Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats.
Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):14040-5. doi: 10.1073/pnas.0506735102. Epub 2005 Sep 16.
2
Single amino acid substitutions in the severe acute respiratory syndrome coronavirus spike glycoprotein determine viral entry and immunogenicity of a major neutralizing domain.
J Virol. 2005 Sep;79(18):11638-46. doi: 10.1128/JVI.79.18.11638-11646.2005.
3
Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine.
Virology. 2005 Sep 30;340(2):174-82. doi: 10.1016/j.virol.2005.06.016.
4
Augmentation of immune responses to SARS coronavirus by a combination of DNA and whole killed virus vaccines.
Vaccine. 2005 Aug 15;23(35):4385-91. doi: 10.1016/j.vaccine.2005.04.011.
5
SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus.
Vaccine. 2005 Oct 10;23(42):4959-68. doi: 10.1016/j.vaccine.2005.05.023.
6
A human SARS-CoV neutralizing antibody against epitope on S2 protein.
Biochem Biophys Res Commun. 2005 Jul 22;333(1):186-93. doi: 10.1016/j.bbrc.2005.05.089.
7
Immunological detection of severe acute respiratory syndrome coronavirus by monoclonal antibodies.
Jpn J Infect Dis. 2005 Apr;58(2):88-94.
8
Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants.
J Virol. 2005 May;79(10):5900-6. doi: 10.1128/JVI.79.10.5900-5906.2005.
9
Immune responses in Balb/c mice induced by a candidate SARS-CoV inactivated vaccine prepared from F69 strain.
Vaccine. 2005 May 2;23(24):3196-201. doi: 10.1016/j.vaccine.2004.11.073.
10
A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies.
J Gen Virol. 2005 May;86(Pt 5):1435-1440. doi: 10.1099/vir.0.80844-0.
Zotero 插件